We present a series of cases of keloid formation after release of syndactyly in the hands and feet of children with associated digital overgrowth. The use of methotrexate to suppress keloid formation after release of syndactyly and for control of recurrence after surgery for keloid is effective.
AbergelRPPizzurroDMeekerCA. Biochemical composition of the connective tissues in keloids and analysis of collagen metabolism in keloid fibroblast cultures. J Invest Dermatol. 1985, 84: 384–90.
AppletonIBrownNJWilloughbyDA. Apoptosis, necrosis, and proliferation: possible implications in the etiology of keloids. Am J Pathol. 1996, 149: 1441–7.
4.
AtiyehBSCostagliolaMHayekSN. Keloid or hypertrophic scar: the controversy: review of the literature. Ann Plast Surg. 2005, 54: 676–80.
BermanBPerezOAKondaS. A review of the biological effects, clinical efficacy, and safety of silicone elastomer sheeting for hypertrophic and keloid scar treatment and management. Dermatol Surg. 2007, 33: 1291–303.
7.
ButlerPDLongakerMTYangGP. Current progress in keloid research and treatment. J Am Coll Surg. 2008, 206: 731–41.
8.
ChenMADavidsonTM. Scar management: prevention and treatment strategies. Curr Opin Otolaryngol Head Neck Surg. 2005, 13: 242–7.
9.
Datubo-BrownD. Keloids: a review of the literature. Br J Plast Surg. 1990, 43: 70–7.
KazeemAA. The immunological aspects of keloid tumour formation. J Surg Oncol. 1988, 38: 16–18.
18.
KellyAP. Medical and surgical therapies for keloids. Dermatol Ther. 2004, 17: 212–18.
19.
KischerCWPindurJKrasovitchPKischerE. Characteristics of granulation tissue which promote hypertrophic scarring. Scanning Microsc. 1990, 4: 877–88.
20.
KischerCWShetlarMRChvapilM. Hypertrophic scars and keloids: a review and new concept concerning their origin. Scan Electron Microsc. 1982, 4: 1699–713.
21.
KoseOWaseemA. Keloids and hypertrophic scars: Are they two different sides of the same coin?Dermatol Surg. 2008, 34: 336–46.
22.
LadinDAHouZPatelD. p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen. 1998, 6: 28–37.
23.
LaurentaciGDioguardiD. HLA antigens in keloids and hypertrophic scars. Arch Dermatol. 1977, 113: 1726–1726.
24.
LeADZhangQWuY. Elevated vascular endothelial growth factor in keloids: relevance to tissue fibrosis. Cells Tissues Organs. 2004, 176: 87–94.
25.
LeFloreIAntoineGA. Keloid formation on palmar surface of hand. J Natl Med Assoc. 1991, 83: 463–4.
26.
LeventhalDFurrMReiterD. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg. 2006, 8: 362–8.
27.
LouwL. The keloid phenomenon: progress toward a solution. Clin Anat. 2007, 20: 3–14.
MeierKNanneyLB. Emerging new drugs for scar reduction. Expert Opin Emerg Drugs. 2006, 11: 39–47.
30.
MessadiDVLeABergS. Expression of apoptosis-associated genes by human dermal scar fibroblasts. Wound Repair Regen. 1999, 7: 511–17.
31.
MustoeTA. Scars and keloids. BMJ. 2004, 328: 1329–30.
32.
MustoeTACooterRDGoldMH. International clinical recommendations on scar management. Plast Reconstr Surg. 2002, 110: 560–71.
33.
MuzaffarARRafolsFMassonJEzakiMCarterPR. Keloid formation after syndactyly reconstruction: associated conditions, prevalence, and preliminary report of a treatment method. J Hand Surg Am. 2004, 29: 201–8.
34.
NiessenFBSpauwenPHSchlakwijkJKonM. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999, 104: 1435–58.
35.
O'BrienLPanditA. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev. 2006, 1: CD003826–CD003826.
36.
Omo-DareP. Genetic studies on keloid. J Natl Med Assoc. 1975, 67: 428–32.
37.
OnwukweMF. Treating keloids by surgery and methotrexate. Arch Dermatol. 1980, 116: 158–158.
38.
O’SullivanSTO’ShaughnessyMO’ConnorTP. Aetiology and management of hypertrophic scars and keloids. Ann R Coll Surg Engl. 1996, 78: 168–75.
39.
PoochareonVNBermanB. New therapies for the management of keloids. J Craniofac Surg. 2003, 14: 654–7.
40.
RockwellWBCohenIKEhrlichHP. Keloids and hypertrophic scars: A comprehensive review. Plast Reconstr Surg. 1989, 84: 827–37.
41.
RoquesCTeotL. The use of corticosteroids to treat keloids: A review. Int J Low Extrem Wounds. 2008, 7: 137–45.
42.
SlempAEKirschnerRE. Keloids and scars: A review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr. 2006, 18: 396–402.
43.
SteinbrechDSMehraraBJChauD. Hypoxia upregulates VEGF production in keloid fibroblasts. Ann Plast Surg. 1999, 42: 514–20.
44.
TonkinMAWillisKRLawsonRD. Keloid formation resulting in acquired syndactyly of an initially normal web space following syndactyly release of an adjacent web space. J Hand Surg Eur. 2008, 33: 29–31.
45.
TredgetEENedelecBScottPGGhaharyA. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg Clin North Am. 1997, 77: 701–30.
46.
TuanTLNichterLS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today. 1998, 4: 19–24.
47.
TuanTLZhuJYSunBNichterLSNimniMELaugWE. Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts. J Invest Dermatol. 1996, 106: 1007–11.
48.
WangXQLiuYKWangZYJiangYZQingXLuSL. Antimitotic drug injections and radiotherapy: A review of the effectiveness of treatment for hypertrophic scars and keloids. Int J Low Extrem Wounds. 2008, 7: 151–9.
49.
WoodVE. Keloid formation in a simple syndactyly release: A case report. J Hand Surg Am. 1992, 17: 479–80.
50.
YangGPLimIJPhanTTLorenzHPLongakerMT. From scarless fetal wounds to keloids: molecular studies in wound healing. Wound Repair Regen. 2003, 11: 411–18.
